Rotating injection sites, moisturizing the skin, and avoiding irritants may help manage symptoms
1 Key results: Semaglutide 2.4 mg: -15.8% body weight loss Liraglutide 3 mg: -6.4% body weight loss Treatment difference: -9.4 percentage points in favour of semaglutide The proportion achieving clinically meaningful weight loss: Important note about Ozempic doses The STEP 8 trial used semaglutide 2.4 mg, which is the Wegovy dose for weight management
Journal of Investigative Dermatology, 128(1), 35-44
Pharmacies across the UK experienced shortages ahead of the hike, with wholesalers pausing orders to manage demand
doi:10.1007/s13300-024-01674-8
Formation of aggregates: In injectables, peptides may clump together into aggregates, which can block needles or cause local irritation at the injection site